SynthesisFrontiers in neurology
Efficacy and safety of ozone autohemotherapy for zoster-associated pain: a meta-analysis and trial sequential analysis.
Synthesis in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the efficacy and safety of ozone autohemotherapy (O₃-AHT) in the treatment of zoster-associated pain (ZAP). Methods: PubMed, Cochrane Library, Web of Science, Embase, Chinese Biomedical Database, China National Knowledge Infrastructure (CNKI), Wanfang Database, and VIP Database were searched on September 10, 2025. We searched for randomized controlled trials evaluating O₃-AHT for ZAP management from database inception to September 10, 2025. Two researchers independently screened the literature, extracted data, and assessed the risk of bias. Data analysis was performed using RevMan 5.4 and Stata 18.0 software to calculate the standardized mean difference (SMD), mean difference (MD), relative risk (RR), and their 95% confidence intervals (CI). Trial sequential analysis (TSA) was conducted using TSA 0.9.5.10 software to assess the robustness of the evidence, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used to evaluate the quality of evidence. Results: A total of 20 studies involving 1,519 patients were included. Meta-analysis revealed that compared with the control group, O Conclusion: O₃-AHT may effectively alleviate ZAP and improve the quality of life and sleep quality through anti-inflammatory and immunomodulatory mechanisms, with a favorable safety profile; moreover, combination therapy may offer greater clinical benefit. However, owing to limitations in the number and quality of included studies, further larger-scale, high-quality randomized controlled trials are warranted. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier: CRD420251145896.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.